Dyslipidemia (Metabolic Drivers)
Metabolically driven dyslipidemia is characterized by high triglycerides, low HDL-C, and a predominance of small dense LDL particles -- the lipid pattern most closely associated with insulin resistance and visceral obesity. This pattern carries a higher cardiovascular risk than isolated LDL elevation and often responds well to metabolic intervention.
Symptoms
Most dyslipidemia is asymptomatic and detected on routine labs. Very high triglycerides (above 1,000 mg/dL) can cause acute pancreatitis with severe abdominal pain. Xanthomas (fatty deposits in skin or tendons) appear in familial hypercholesterolemia.
Causes and risk
Insulin resistance is the primary driver of the atherogenic dyslipidemia pattern. Contributory factors include obesity, type 2 diabetes, hypothyroidism, chronic kidney disease, alcohol use, and medications such as corticosteroids, beta-blockers, and oral contraceptives.
How it is evaluated
Beyond a standard lipid panel, we assess non-HDL-C, apolipoprotein B (a superior marker of atherogenic particle burden), and lipoprotein(a) when cardiovascular risk is unclear. Fasting glucose and insulin are checked to confirm the metabolic context.
Treatment
For metabolically driven dyslipidemia, weight loss and carbohydrate reduction improve all components simultaneously. Statins are added based on ASCVD risk score. Fibrates, omega-3 fatty acids, and niacin target hypertriglyceridemia. PCSK9 inhibitors are used in high-risk patients or familial hypercholesterolemia.